VEGFA and hemorrhage: It is presumed to be a result of the hypoxia-induced capillary permeability after vein occlusion and subsequent hemorrhage.[15] The most popular treatment in CRVO is the intravitreal injection of an anti-VEGF, such as bevacizumab, ranibizumab, and aflibercept.